Teligent Pharma, Inc.’s Issues Voluntary Recall of Lidocaine HCl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due to Super Potency

Healthcare Professional
Written By Denise Kolakowski
depositphotos_37864801-stock-photo-glass-medicine-vials.jpg
Learn more from the fda
Learn more from the fda
Denise Kolakowski
Previous

FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Next

Michigan Poison & Drug Information Center warns of risks of misuse of Ivermectin for treatment or prevention of COVID-19